Drug news
Biocon withdraws application for trastuzumab biosimilar from EMA
The European Medicines Agency has found issues with the Biocon product plant in Bangalore. It told Mylan and Biocon that a follow-up inspection would be in order before the trastuzumab biosimilar and a biosimilar of Amgen�s Neulasta will be considered for approval .Biocon Ltd. said it will withdraw its application for EU approval of its biosimilar version of Roche's blockbuster cancer drug Herceptin, after the European Medicines Agency informed the company it would need to re-inspect a drug product facility.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.